These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27135253)

  • 1. Platelet phenotype changes associated with breast cancer and its treatment.
    Holmes CE; Levis JE; Schneider DJ; Bambace NM; Sharma D; Lal I; Wood ME; Muss HB
    Platelets; 2016 Nov; 27(7):703-711. PubMed ID: 27135253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
    Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
    Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
    Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
    Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets.
    Bambace NM; Levis JE; Holmes CE
    Platelets; 2010; 21(2):85-93. PubMed ID: 20063989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
    Kassassir H; Siewiera K; Sychowski R; Watała C
    Pharmacol Rep; 2013; 65(4):870-83. PubMed ID: 24145081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis.
    Liu Z; Xiang Q; Mu G; Xie Q; Zhou S; Wang Z; Chen S; Hu K; Gong Y; Jiang J; Cui Y
    Platelets; 2020; 31(1):3-14. PubMed ID: 30744477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis.
    Solanilla A; Villeneuve J; Auguste P; Hugues M; Alioum A; Lepreux S; Ducroix JP; Duhaut P; Conri C; Viallard JF; Nurden AT; Constans J; Ripoche J
    Rheumatology (Oxford); 2009 Sep; 48(9):1036-44. PubMed ID: 19549789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
    Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
    Kamada A; Shimizu M; Oura K; Yoshida M; Tsuda K; Oi K; Ishigaku Y; Natori T; Narumi S; Itabashi R; Maeda T; Terayama Y
    J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105547. PubMed ID: 33360254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor.
    Mingant F; Didier R; Gilard M; Martin F; Nicol PP; Ugo V; Lippert E; Galinat H
    Platelets; 2018 May; 29(3):257-264. PubMed ID: 29580115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P2Y
    Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2Y12 Receptor Modulates Sepsis-Induced Inflammation.
    Liverani E; Rico MC; Tsygankov AY; Kilpatrick LE; Kunapuli SP
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):961-71. PubMed ID: 27055904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelets Express Activated P2Y
    Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
    Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
    Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
    Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V; Armstrong PC; Warner TD; Curzen N
    Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.